This Humanized Monoclonal antibody specifically detects Trop2 (Sacituzumab Biosimilar) in FACS and in vivo. It exhibits reactivity toward Human.
Catalog No. ABIN7795133
Quick Overview for Recombinant Trop2 (Sacituzumab Biosimilar) antibody (ABIN7795133)
Target
Trop2 (Sacituzumab Biosimilar)
Antibody Type
Recombinant Antibody
Reactivity
Human
Host
Humanized
Clonality
Monoclonal
Conjugate
This Trop2 (Sacituzumab Biosimilar) antibody is un-conjugated
Application
Flow Cytometry (FACS), In vivo Studies (in vivo)
Grade
Research Grade
Expression System
Mammalian cells
Purpose
Sacituzumab Biosimilar, Endotoxin 0.05 EU/mg
Characteristics
What is sacituzumab biosimilar research grade? Sacituzumab Biosimilar uses the same protein sequences as the therapeutic antibody sacituzumab. Sacituzumab govitecan is a Trop-2-directed antibody and topoisomerase inhibitor drug conjugate used for the treatment of metastatic triple-negative breast cancer and metastatic urothelial cancer. Triple-negative breast cancer is a type of breast cancer that tests negative for estrogen receptors, progesterone receptors and human epidermal growth factor receptor 2 (HER2) protein. Therefore, triple-negative breast cancer does not respond to hormonal therapy medicines or medicines that target HER2. Sacituzumab govitecan is a conjugate of the humanized anti-Trop-2 monoclonal antibody linked with SN-38, the active metabolite of irinotecan. Each antibody having on average 7.6 Molecules of SN-38 attached. SN-38 is too toxic to administer directly to patients, but linkage to an antibody allows the drug to specifically target cells containing Trop-2.
Purification
Protein A or G affinity column
Purity
>95 % by reducing SDS-PAGE
Endotoxin Level
Less than 0.5 EU/mg of protein as determined by LAL method